| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 73.9MM | +10% |
| Gross Profit | 31.1MM | +26% |
| Cost Of Revenue | 42.8MM | +0% |
| Operating Income | 14.2MM | +64% |
| Operating Expenses | 16.9MM | +6% |
| Net Income | -17.6MM | -788% |
| R&D | 445.5K | -25% |
| G&A | 15.5MM | +5% |
| Amortization | 187.5K | +5% |
| Interest Expense | 6.2MM | -3% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Adma Biologics (ADMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
In the most recent trading session, Adma Biologics (ADMA) closed at $6.27, indicating a +1.13% shift from the previous trading day.
Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.
In the most recent trading session, Adma Biologics (ADMA) closed at $6.04, indicating a -1.95% shift from the previous trading day.
Here is how Annexon, Inc. (ANNX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.
Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.
Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.
J&J (JNJ) beats estimates for first-quarter earnings but misses the same for sales. It tightens its sales and earnings growth expectations for 2024.
Adma Biologics (ADMA) closed at $6.04 in the latest trading session, marking a -1.15% move from the prior day.